Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Indolent Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00005950
What this trial is testing

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Who this might be right for
Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+7 more
National Cancer Institute (NCI) 111
Testing effectiveness (Phase 2)Study completedNCT00244985
What this trial is testing

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Roswell Park Cancer Institute 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149
What this trial is testing

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Who this might be right for
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more
Patrick C. Johnson, MD 28
Early research (Phase 1)Study completedNCT04136756
What this trial is testing

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaIndolent Non-Hodgkin Lymphoma
Nektar Therapeutics 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04245839
What this trial is testing

Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 276
Large-scale testing (Phase 3)Ended earlyNCT00060671
What this trial is testing

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, FollicularLymphoma, Mixed-Cell, FollicularLymphoma, Small Cleaved-Cell, Follicular+1 more
CTI BioPharma 800
Large-scale testing (Phase 3)WithdrawnNCT00577161
What this trial is testing

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Who this might be right for
Non-Hodgkin's Lymphoma
CTI BioPharma
Early research (Phase 1)UnknownNCT03588598
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)B-Cell Non-Hodgkin Lymphomas(NHL)
Nanjing Sanhome Pharmaceutical, Co., Ltd. 40
Early research (Phase 1)Study completedNCT00621452
What this trial is testing

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+8 more
Fred Hutchinson Cancer Center 12
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Testing effectiveness (Phase 2)Ended earlyNCT02811679
What this trial is testing

Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Massachusetts General Hospital 13
Testing effectiveness (Phase 2)Looking for participantsNCT06986174
What this trial is testing

Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Who this might be right for
Waldenström MacroglobulinemiaLymphoplasmacytic LymphomaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD 30
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT00868608
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Who this might be right for
Lymphoma
Pfizer 81
Testing effectiveness (Phase 2)Ended earlyNCT01796470
What this trial is testing

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+1 more
Gilead Sciences 66
Testing effectiveness (Phase 2)Ended earlyNCT05328102
What this trial is testing

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large-cell B-cell Lymphoma
Xencor, Inc. 3
Not applicableStudy completedNCT05217914
What this trial is testing

Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Who this might be right for
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Bayer 6
Testing effectiveness (Phase 2)Study completedNCT02342665
What this trial is testing

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Who this might be right for
Lymphoma Non-Hodgkin
Bayer 25
Next Page